

**OPENING PLENARY SPEAKERS (in chronological order)**



**Tom Luby, Ph.D**  
**Director**  
**TMC Innovation**

Tom Luby was born on Long Island, New York and grew up in a small town called Yaphank. Before beginning his professional career working in the health care startup industry, Tom received a Bachelor of Science in Biology from State University of New York and a Ph.D. in Immunology from the Sackler School of Biomedical Sciences at Tufts University. For his post-doctoral research, Tom shifted to the study of cancer cell genetics at Harvard School of Public Health.

Prior to making his way down to Houston, Texas Medical Center, and TMC Innovation, Tom served as New Ventures Lead at Johnson & Johnson Innovation, Boston, where he was instrumental in closing many deals with pharmaceutical and consumer companies and supporting the JLABS sites in Toronto and Boston. In addition, Tom spent 14 years in various R&D and business development positions, including Senior Director of Research Ventures at Shire. Nine of those years were spent working in R&D and operational roles across three startup biotech companies in the Boston area.

In his previous role as Head of JLABS @ TMC, a part of the Johnson & Johnson Innovation family, Tom was the site head and played a critical role in creating a place where startups could translate science and technology into valuable solutions for patients and consumers across the pharmaceutical, medical device, and consumer health technology sectors.

Now, Tom is eager to expand his role at TMC Innovation and help scale the collective innovation ecosystem within the walls of the former Nabisco cookie factory. “I have always enjoyed working closely with health care startups,” Tom commented. He added, “Every startup is different and requires a singular focus; creating a startup is immensely difficult, and helping companies beat the odds and become successful always gives all of us a sense of pride. Their solutions are our gateway to higher-quality and healthier lives.”

In his spare time, Tom spearheads another complex operation – his family. Tom and his wife Jen have four kids (two at home, two in college), two cats, and one dog. Collectively, they enjoy dinners out – or at home – with each other. They also have a summer home on Cape Cod that presents a rare annual opportunity for extended relaxation! Tom also enjoys playing golf, reading copious amounts of newspapers each day, and skipping commercials during movies and live sports by utilizing one of his favorite new technologies – on-demand viewing.

In conclusion, Tom emphasized, “I’ve been fortunate in my career to work with some outstanding people who have served as mentors – including Robert Urban and Mary Lynne Hedley in Boston, among many others, and Billy Cohn here in Houston.” He added, “Along the way, I’ve tried my best to work hard, stay humble, and show respect to others. I plan to never lose sight of those tenets and will carry them with me into my new role at TMC Innovation.”



**Jose-Manuel (Chema) Collados**  
**Healthcare Solutions Line Manager**  
**ABB Robotics for Healthcare**

Jose-Manuel (Chema) Collados is originally from Spain. He graduated from the University of Zaragoza in 1998 with a degree in Industrial Engineering, with Specialization in Electronics and Automation. He had his first contact with mobile robotics in 1997, when he participated in a project in Laboratory of Analysis and Architecture of Systems (LAAS) de Toulouse.

In the beginning of 1999, he joined ABB where he learned by participating in different departments: robotics, project engineering, execution and sales. He worked 10 years as global key account manager.

He then moved to the ABB Power business to become part of the solar renewable energy project team. In the last years, he has worked as business manager in ABB Spain for Power Conversion, Industrial Drives and Robotics and Motion businesses where he could pursue some of his larger passions: building and maintaining strong teams that were able to grow and develop new businesses in the fields of automation, power, electrical mobility and traction.

Since August, he has been part of the TMC Innovation community in Houston, leading the new ABB Robotics for Healthcare Global Accelerator.



**Annie Kadota**  
**Vice President: Southwest Life Science**  
**Silicon Valley Bank**

Annie Kadota is a vice president in Silicon Valley Bank's Life Science and Healthcare Banking Solutions group, Southwest Region, where her specialty in venture debt supports the team's deep expertise in providing financial solutions to high-growth public and private life science companies.

Annie joined Silicon Valley Bank in 2014 based in the Bay Area and returned to her hometown of San Diego in 2015 to join the Life Science Practice. Annie also serves as a committee chair for the Southern California chapter of Women in Bio, which promotes careers, leadership and entrepreneurship in the second-largest biotech hub in the United States.

Annie graduated with a bachelor's degree in sports management from Rice University, where she'd earned numerous academic and athletic awards as a four-year letter winner on the varsity soccer team. Outside of the office, Annie enjoys playing soccer, skiing in Whistler, and practicing piano/guitar.



**Ariana Ognibene**  
**Vice President: Southwest Life Science**  
**Silicon Valley Bank**

Ariana Ognibene is a vice president on Silicon Valley Bank's Life Science and Healthcare team, covering the Medical Device and Digital Health sectors for the Southwest US region. She specializes in devising innovative financial solutions and providing venture debt to highly unique and fast-growing public and private life science companies across varying stages of development.

Ariana originally joined Silicon Valley Bank in 2015 in her hometown of Boston, Massachusetts.

She began supporting the Bank's Northeast Life Science practice there in 2017 and more recently migrated to the west coast to support the Southwest Life Science Team in 2018 based out of San Diego, California. Outside of the San Diego office she also spends her time keeping a pulse on the Life Science industry as a member of Biocom's Medical Device Committee.

Ariana graduated with a Bachelor's degree in Economics from College of the Holy Cross located in Worcester, MA. She is the oldest of three sisters and two dogs in her family who are all still located in the Boston area. Outside of the office, Ariana enjoys various genres of dance after being a dancer for fifteen years. She also enjoys running, hiking, and Italian food.



**Chris Haskell, Ph.D.**  
**VP, Head Open Innovation Center – North America West**  
**Bayer**

Dr. Christopher Haskell leads Bayer's U.S. Science Hub, based in the company's U.S. Innovation Center located at Mission Bay, San Francisco. Haskell and his group support Bayer's Global Drug Discovery through developing and managing partnerships with US academic research institutions and emerging life science firms, including the master agreement signed with UCSF in 2010. Haskell is also responsible for the development of the CoLaborator, a biotech incubator space adjacent to the company's U.S. Innovation Center that opened in the fall of 2012 in San Francisco. The CoLaborator houses a number of startup life science firms, and has been developed as a vehicle to foster collaboration between Bayer and these emerging innovators.

After his graduate work at the University of California, Davis and a postdoctoral fellowship at The Gladstone Institute in San Francisco, Haskell joined the Immunology group at Berlex Biosciences. Since joining Bayer in 2007, Haskell has served in various scientific leadership roles, including the Acting Head of Applied Research, the unit responsible for hemostasis research and drug development. In late 2009, Haskell was named head of Bayer's newly formed Science Hub.

**SPEAKERS (alphabetized by surname)**



**Frank Amini, Ph.D., J.D.**  
**Associate**  
**Winstead**

Frank Amini is an associate in Winstead's Intellectual Property Practice Group with substantial experience in patent prosecution, intellectual property licensing, and related intellectual property transactions.

Frank has written and prosecuted numerous patent applications in various technological areas, including materials science, nanotechnology, biotechnology, the life sciences, and the chemical arts. Frank's patent prosecution experience has spanned the following areas:

- Fabrication of various carbon nanomaterials (e.g., carbon nanotubes, graphenes, graphene nanoribbons, graphene oxides, graphene quantum dots, graphene nanoplatelets, etc.);
- Use of carbon nanomaterials for water and air purification;
- Use of carbon nanomaterials for imaging, purifying and detecting hydrocarbons;
- Use of carbon nanomaterials for the delivery of active agents into cells;
- Use of carbon nanomaterials for the fabrication of energy storage devices;
- Use of small molecules for chemical detection, imaging, enzyme inhibition, and disease treatment;
- Use of pharmaceutical compositions for drug delivery;
- Fabrication of inorganic or ceramic compositions (e.g., cement, adhesive materials, conductive materials, electrolytes, etc.) for various purposes.

In addition, Frank has drafted and negotiated numerous intellectual property licensing agreements for various technologies, including medical diagnostics and fluid purification processes.

Frank also has experience in the following areas of intellectual property law:

- Preparation of freedom to operate opinions;
- Rendering opinions regarding patentability and patent infringement;
- Providing assistance with intellectual property litigation matters, including the review of discovery documents and the preparation of witnesses for depositions;
- Evaluation of the intellectual property portfolios of various companies and institutions in connection with mergers, acquisitions, and capital investments;
- Devising intellectual property protection strategies that include the utilization of patents, trademarks, copyrights, and trade secrets.

Prior to joining Winstead, Frank was a technical specialist at a Chicago law firm, where he assisted attorneys with the evaluation and management of various patent litigation cases in different technological areas, including pharmaceuticals, bio-therapeutics, medical devices, and mechanical devices. Frank also began his legal studies in Chicago. Prior to that, Frank worked on the development of a novel protein labeling method as a graduate student at the University of Texas Southwestern Medical Center in Dallas.

Frank has also served as a pre-doctoral fellow at the National Institutes of Health, where he conducted research on the role of a novel protein on the regulation of gene expression in mice. In addition, he has research experience in the field of microbial genetics.

Co-author of the WinTech blog, which provides legal insight for start-up and established technology businesses.



**Lance Black, M.D.**  
**Associate Director**  
**TMCx Accelerator**

Lance Black, MD, MBID, is the Associate Director of the Texas Medical Center's TMCx Accelerator program.

Dr. Black served previously as Medical Device Innovation Lead, and draws on his extensive military, medical, and engineering expertise to support the resident companies of TMCx in developing innovative healthcare technologies.

After earning his B.S. in Biological Engineering from Louisiana State University and his M.D. from LSU Health Sciences Center of New Orleans, Dr. Black served in the U.S. Air Force and deployed overseas twice: first as Chief of Medical Staff for Manas Transit Base in Kyrgyzstan, and then as a Squadron Flight Surgeon in Okinawa, Japan.

During his time in the armed forces, Dr. Black helped to create modular medical facilities for civilian use, and designed and implemented safety protocols for F-22 stealth fighter pilots and their crews.

Inspired from his work with Wounded Warrior amputees, Dr. Black utilized his background in Biological Engineering to focus on the design and development of medical devices. Following his exit from service, Dr. Black received his Masters of Biomedical Innovation & Development from Georgia Tech, including a year in their Masters of Industrial Design program.



**Colin Broom**  
**CEO**  
**Pulmotect**

Dr. Broom has been our CEO since September 2019. Over the past 30 years he has been involved in all stages of drug development and commercialization across multiple therapeutic areas including oncology, anti-infectives and pulmonary medicine. He served as CEO of Nabriva Therapeutics plc until July 2018 and remains a member of the Board of Directors. Previously he was Chief Scientific Officer at ViroPharma Inc. until its acquisition by Shire in 2014 and was a member of the Board of NPS Pharmaceuticals. Previous positions include a range of international leadership roles with Amgen, SmithKline Beecham and Glaxo (now Glaxo SmithKline). He has a BSc in Pharmacology from University College, London and received his medical degree and clinical training at St George's Hospital Medical School in London. He is a member of the Royal College of Physicians of the UK and a fellow of the Faculty of Pharmaceutical Medicine.



**Brad Burke**  
**Managing Director**  
**Rice Alliance for Technology and Entrepreneurship**

Brad Burke is the Managing Director of the Rice Alliance and has led the Rice Alliance since 2001. During that time, Rice's graduate entrepreneurship program has achieved the #3 ranking in the U.S. (having been previously unranked). The Rice Alliance's Rice Business Plan Competition has become the world's largest and richest student startup competition in the world. Previously, Brad founded and managed the Houston office of Viant Corporation, a premier internet consulting firm, that went public via IPO in 1999, before being acquired in 2002. Prior to Viant, Brad was a Principal with CSC Index, the former management consulting division of Computer Sciences Corporation

(CSC). Before CSC, Brad held executive management positions with Exxon. He received his M.B.A. from Northwestern University's Kellogg Graduate School of Management as an Austin Scholar and his B.S. from Vanderbilt University.



**Terri Burke**  
**Venture Partner**  
**Epidarex Capital**

Terri Burke is both a Venture Partner with Epidarex Capital, where she leads the MedTech investment strategy, and co-founder and CEO of Protaryx Medical. Previously, Terri was a member of the Senior Leadership Team at Edwards Lifesciences and held multiple Vice President positions including managing a cross-functional technical development program, leading Global Marketing, and overseeing Business Development for several strategic acquisitions and partnerships. Terri has prior experience in health economics and reimbursement as a consultant with Covance and in product marketing with Guidant Corporation.

Terri holds a Board Director role with Raydiant Oximetry, is an active member of MedtechWOMEN and is a founding member of the Duke Women's Impact Network Athletics Leadership Council. Terri holds a B.S. in Biology from Duke University and an MBA from the University of Southern California.



**Heath Butler**  
**Network Partner**  
**Mercury Fund**

1) I am senior-level executive with over 15 years of experience as a transformational leader with an accomplished background in strategic goal deployment and accelerating business growth.

2) I love to leverage my simultaneous right-brain/left-brain talents for strong creative and analytical solutions that enable me to thoroughly strategize and decisively execute objectives.

3) I am passionate about educating, empowering and enabling entrepreneurs, angel investors and business professionals to maximize their potential.

Here are some specialty details about my skills, knowledge and experiences:

- Visionary, Strategy, Execution & Leadership
- P&L Optimization
- Growth & Business Development Playbooks
- Go-to-Market Strategy & Execution
- Channel Strategy & Execution
- Mergers & Acquisitions
- Due Diligence, Deal Structuring & Negotiations
- Product Development & Marketing Launch
- Operations Management Efficiency
- Industry, Market & Competitive Analysis
- Startup, Turnaround & Change Management



**Joseph Conrad, Ph.D., J.D.**  
**Senior Technology Transfer Manager, Invention Development & Marketing Unit,**  
**Technology Transfer Center**  
**National Cancer Institute**

Joseph M. Conrad III earned his Ph.D. in biochemistry from American University in 1995, while working as a chemical/pharmaceutical patent Examiner at the U.S. Patent & Trademark Office. The following year, he started law school at George Washington University Washington College of Law where he received his JD in 2000. While in law school, he joined the Washington, DC law office of Pillsbury Madison & Sutro, LLP as a patent agent, and after graduation, joined the DC patent law firm of Sterne Kessler Goldstein & Fox PLLC. He joined the National Institute of Allergy and Infectious Diseases' (NIAID's) Office of Technology Development (OTD) in 2003, where he was responsible for the management of NIAID's patent portfolio and educating scientists on patent related matters. In 2006, he joined the National Cancer Institute's (NCI's) Technology Transfer Center (TTC), where he was responsible for negotiating technology transfer agreements and overseeing invention activities for the National Institute of Child Health and Human Development (NICHD). He recently joined TTC's Invention Development and Marketing Unit (IDMU) as a Technology Transfer Marketing Specialist. In this new position, Dr. Conrad is responsible for developing and improving TTC technology marketing activities; increasing awareness of licensing and partnering opportunities with the NCI (and other NIH Institutes); increasing technology visibility to the private sector and improving relationships with private sector stakeholders.



**Casey Cunningham, M.D.**  
**Chief Scientific Officer**  
**Santé Ventures**

Casey Cunningham, M.D. is the Chief Scientific Officer of Santé Ventures. Dr. Cunningham received his fellowship training in oncology and hematology at Harvard Medical School, where he subsequently served on the faculty. He was also one of the founding members of the Division of Experimental Medicine at the Brigham & Women's Hospital in Boston, where he established a basic research laboratory in Cell and Molecular Biology.

He has over 70 publications in peer-reviewed journals and many abstracts and meeting presentations. Casey received his medical degree from the University of Texas Southwestern Medical School with a residency in Internal Medicine at the Medical College of Wisconsin. Casey returned to Texas in 1999 as the Associate Director of the Mary Crowley Cancer Research Center in Dallas, a position he held until 2007. He joined Santé Ventures shortly after its founding. He has served in operating roles in Terapio, Molecular Templates and Beta Cat Pharmaceuticals and has been, or is currently on, the Boards of Geneos Therapeutics, Terapio Corp., Molecular Templates, Lyric Pharmaceuticals, AbVitro and Mirna Therapeutics.



**Larry Denner, Ph.D.**  
**Professor**  
**UTMB, Galveston**

Dr. Larry Denner, Ph.D., is Director for Discovery Research and Translation, the McCoy Distinguished Professor of Medicine, and Founder and Chief Scientific Officer of Cord Blood Plus, Inc. at the University of Texas Medical Branch in Galveston. Most recently he discovered revolutionary umbilical cord blood expansion technology and is one of the leading experts in the field of stem cell expansion. He has many years of experience in academic translational research and start-

ups. He was one of the first employees at the startup drug discovery and development company Encysive Pharmaceuticals (ENCY) in the Texas Medical Center where he spent over 12 years. During that time he was also co-founder of a spin-off company, Revotar Biopharmaceuticals AG, in Berlin, Germany. Dr. Denner received his BS in Biology from the University of California, Irvine, and his Ph.D. in Neuroscience at Baylor College of Medicine in Houston.




**Stephan Gauldie, Ph.D.**  
**Senior Vice President**  
**Back Bay Life Science Advisors**

Dr. Stephan Gauldie joined Back Bay at its founding in 2010 and has been active in building the firm's offering across company size and sector. His role places particular emphasis on Strategic Franchise Building, M&A and Licensing Strategy, Buy Side Diligence, and Liquidity Planning and Positioning for Emerging Growth Companies. In addition to his senior consulting role, Stephan is a member of Back Bay's Financial Advisory team, providing market and scientific analytics in Sell Side and Buy Side engagements.

Stephan has over 15 years of experience across drug development research, market analysis, and strategy consulting. Prior to joining Back Bay, he led the Commercial Research Group at Decision Resources and was a Principal Analyst at Wood Mackenzie, leading teams that covered US and EU-based pharmaceutical companies, as well as CNS/Pain and Immunology therapeutic areas.

Stephan obtained his doctorate in Neuropharmacology from the University of Edinburgh Medical School, in collaboration with GlaxoSmithKline's Neurology and Gastrointestinal Center for Early Drug Discovery (CEDD), and completed a post-doctoral fellowship in the Department of Pharmacology at the same institution.

Stephan also holds undergraduate degrees in Medicinal Chemistry and Psychology from Queen's University, Canada.



**Heather Giles, Ph.D.**  
**President & CEO**  
**Vapogenix**

Dr. Giles has held international leadership positions in large and small pharmaceutical companies, and has wide experience in drug discovery and development from target validation, through clinical studies to final regulatory submission. She has expertise in numerous therapeutic areas and a track-record of delivering new drugs into development and on to market.

Dr. Giles joined Vapogenix in 2009 as Chief Scientific Officer and has provided scientific and drug development leadership, in addition to making significant contributions to overall company strategy and to successful fundraising. She was appointed President, CEO and Director in July 2017. Previously, from 2001 to 2008, she was Vice-President of Strategic Planning at Encysive, a small pharmaceutical company in Houston, Texas. There she managed the R&D portfolio and played a pivotal role in delivering the company's key development product, to regulatory submission and subsequent European commercial launch. Prior to Encysive, Dr. Giles was International Disease Strategy Director for Asthma at GlaxoSmithKline R&D and prior to this was Head of the Receptor Pharmacology department at GlaxoWellcome R&D, UK (1995-2000). From 1983-1995, at Wellcome R&D, UK, she held various research, project leader and management positions.

She has an extensive scientific publication record and currently serves as adjunct Associate Professor in the Department of Pharmacology at the University of Houston. She is a member of the British Pharmacological Society and has served on their governing council and on the Editorial Board Editor for the British Journal of Pharmacology.



**Kurt Harris**  
**Director**  
**Carta**


Kurt Harris is a Director on Carta's Partnerships team. The partnership team ensures that channel partners (including law firms, accelerators, and VC funds) have appropriate training and materials to deliver exceptional user experiences for their clients on the Carta platform.

Prior to Carta, Kurt worked as a Vice President for a national valuation firm, a Manager in J.P.Morgan's commercial bank, and was a Platoon Sergeant with the U.S. Marine Corps. He holds undergraduate and master's degrees in music and finance from the University of Utah and is a Level II CFA Candidate.



**Michelle Ho**  
**Analyst**  
**5AM Ventures**

Michelle Ho, Ph.D., is an Analyst at 5AM Ventures. Dr. Ho joined in 2018 from Fannin Innovation Studio where she was an Entrepreneurship Fellow leading R&D and business development for two early stage life science startups in Houston, TX. Prior to Fannin, Dr. Ho was a T32 Postdoctoral Fellow in the Department of Gynecologic Oncology at The University of Texas M.D. Anderson and the Department of Bioengineering at Rice University developing targeted gene therapy vectors for ovarian cancer treatment. Dr. Ho earned her Ph.D. in Bioengineering from Rice University developing next-generation virus-based gene therapy vectors through design-based capsid protein engineering. She received her B.S. in Bioengineering from the University of California – Berkeley. Dr. Ho is based in the San Francisco, CA office.



**Taha Jangda**  
**Partner**  
**HealthX Ventures**

Medical school dropout turned venture capitalist, Taha is a partner at HealthX Ventures. Taha invests in fast-growing digital health-based companies to drive a profound impact in healthcare. In addition to focusing on strategic investments, he also advises various innovation communities across the country. Taha started his journey at the Texas Medical Center (TMC), the world's largest medical center. During his time with TMC, he took part in the creation of the TMC Innovation Institute which is comprised of a healthcare and life science startup accelerator/incubator, Johnson & Johnson Innovation Center for Device Innovation and JLABS, and AT&T Connected Health Foundry. Having seen firsthand how a lack of integration hinders patient care, Taha followed his entrepreneurial spirit and later joined Redox as Strategic Partnerships to help digital solutions get into the hands of care providers faster. Beyond tackling today's most challenging healthcare issues, Taha spends his free time reading books on leadership development and staying true to his Texas roots – BBQ and football.



**Derek Maetzold**  
**President, CEO & Founder**  
**Castle Biosciences**

Derek J. Maetzold founded Castle Biosciences in September 2007 and has served as our President and Chief Executive Officer and as a member of our board of directors since inception. Previously, Mr. Maetzold held leadership roles at Encysive Pharmaceuticals, Schering-Plough Corporation (now Merck), Integrated Communications, Amylin Pharmaceuticals and Sandoz Pharmaceuticals (now a division of Novartis). Mr. Maetzold currently serves as a director of the Ocular Melanoma Foundation. He has contributed to the discovery, development and commercialization of five diagnostic and prognostic tests in cancers, has co-authored multiple scientific publications and is a co-inventor of a number of technologies at Castle Biosciences and Encysive Pharmaceuticals. Mr. Maetzold holds a B.S. degree in Biology from George Mason University and completed additional coursework at the University of Calgary Health Sciences Center and the MBA program at the University of California, Riverside.



**Tim Marx**  
**Venture Partner**  
**Baird Capital**

Tim Marx is an independent consultant that has been providing his expert advice to Baird Capital since 2018. Marx, working as an advisor, will work with Baird Capital's Venture team to pursue new investment opportunities and help build value within the existing portfolio. With two decades of experience in the consulting and corporate strategy sector, Marx most recently worked as Partner and Managing Director of The Boston Consulting Group (BCG). Marx has worked domestically at Morgan Stanley and internationally at Grupo Financiero Banorte (Mexico). Marx also serves as an advisor and mentor for TMCx, Texas Medical Center's accelerator program, and Station Houston, Houston's hub for tech startups, entrepreneurs and innovation, in addition to his role as Senior Advisor for several start-ups.

Marx holds a Bachelor's degree in Finance, International Business and Spanish from The Pennsylvania State University and a Master's degree of Business Administration from Stanford Graduate School of Business. He was a 2000-01 Fulbright Scholar at ITESM in Monterrey, Mexico."



**Eric Newman**  
**Senior Vice President, ProTecht Risk Solutions**  
**Falvey Cargo Underwriting**

Eric Newman is Senior Vice President of ProTecht Risk Solutions, a division of Falvey Cargo Underwriting. ProTecht Risk Solutions is responsible for providing claims, recovery and loss prevention services. As practice leader for life science and cold chain management, Eric also provides consultative services in risk mitigation programs and operating practices. Eric consults directly with life science clients as a loss prevention resource in all facets of supply chain management and distribution, including development and implementation of packing, shipping, and storage procedures and protocols that are aligned with industry best practices.

A graduate of the Massachusetts Maritime Academy with a BA in Marine Transportation, Eric sailed as a USCG licensed merchant marine officer aboard ocean going commercial cargo vessels. After completing his sailing career, Eric worked as an independent marine cargo surveyor/consultant for 15 years performing a variety of marine insurance-related surveys and inspections involving

all types of cargo shipped via ocean, air, road and rail. During this time, Eric received extensive training in large property/HPR loss prevention inspections and compliance audits of 3PL facilities involved with storage and distribution of life science products and materials.

In 2003, Eric started Newman Marine, Inc., an independent marine risk management company that provided loss prevention and risk management consultation to insurance companies as well as pharmaceutical and high technology manufacturing companies.

Since beginning his career with Falvey in March 2007, Eric has been an active member of the Parenteral Drug Association's (PDA) Pharmaceutical Cold Chain Interest Group (PCCIG). As a member of the PCCIG, Eric was a contributing author for 2 published PDA technical reports on risk management for temperature-controlled distribution (T.R. 58) and active shipping system qualification guidelines (T.R. 64).

Eric is also involved with several other industry organizations involved with development of industry best practices for packaging, shipping and storing temperature sensitive products. These organizations include the Pharmaceutical Cargo Security Coalition (PCSC), Transported Asset Protection Association (TAPA) an Coalition of New England Companies for Trade. Eric is also an active member of the board of advisors for the International Maritime Business program at the Massachusetts Maritime Academy.



**Greg Phillips, J.D.**  
**Partner & Co-Founder**  
**Phillips Kaiser**

In addition to co-founding Phillips Kaiser PLLC and serving on the firm's Management Committee, Greg has an extensive legal career that includes being the Associate General Counsel of Compaq Computer Corporation, Assistant General Counsel of Enron Corp., Vice President and General Counsel of Petroci-USA, Inc. (the United States based wholly-owned subsidiary of the national oil company of the Republic of Cote d'Ivoire, Africa, which was primarily engaged in the acquisition of proven developed natural gas and oil properties in the Gulf Coast States of the United States), and a Corporate Securities Associate at the law firm of Bracewell & Giuliani. He was also formerly the founder of a multi-city Texas law firm, Phillips & Reiter, PLLC, and Managing Director of Morae Legal Corporation.

Greg began his legal career as an Associate in the Corporate Securities group of Bracewell & Giuliani. He later served as an Associate General Counsel at Compaq Computer Corporation supporting various business units, including the Compaq Business Development group in the acquisition of companies such as Digital Equipment Corporation. He also supported all aspects of Compaq's operations which included logistics and the construction, or acquisition, of several worldwide computer manufacturing plants in Brazil and China. Greg also served as an Assistant General Counsel for the Enron Bankruptcy Estate where he was responsible for providing legal support in the post-bankruptcy assembling together of various Enron Corp. international assets for sale to create value for the Enron Bankruptcy Estate. In addition, he also managed a team in the dissolution of over 3,000 Enron subsidiaries worldwide during the Enron bankruptcy.

In addition to representing clients in corporate transactional matters in numerous industries, Greg has extensive experience with business development transactions and the negotiation and management of commercial contracts for the midstream and downstream oil & gas industry, including day-to-day crude oil, natural gas or natural gas liquids processing, transportation and storage activities as well as acquisitions and divestitures. He has expertise in providing legal support

## SPEAKERS | 2019 TEXAS LIFE SCIENCE FORUM

in the gathering and processing aspects of the natural gas and crude oil midstream industry as well as the petrochemical industry. His work includes the drafting and implementing of joint ventures and long-term gas and crude oil gathering, processing and transportation, and storage transactions. He also has experience with pipeline and offloading operations for the petrochemical, crude oil, natural gas and natural gas liquids businesses. He also assists clients in developing and analyzing their overall business strategies and various activities, business structures and other relationships to comply with various federal, state or local statutes and regulations.

Despite all of his many accomplishments, Greg's proudest accomplishment is marrying his wife, Cynthia, and creating a loving family with their three children.

### Education and Activities:

- B.S., Engineering Management, Southern Methodist University.
- J.D., University of Texas School of Law.
- M. Div., Summa Cum-Laude, Amridge University.
- Adjunct Professor of Old Testament Survey and Christian Ethics courses at Southwestern Christian College – 2013 to Present.
- Advisory Board Member, BBVA Compass Bank – 2013 to 2015.
- Advisory Board Chairman, Houston Technology Center – 2009 to 2011.
- Board Member, The Houston Angel Network – 2005 to 2011.
- Board Member, The Houston East End Chamber of Commerce – 2009 to 2011.
- Board Member, St. Thomas High School, Houston, Texas – 2011 to 2014.
- Chairman of the Board and Board Member, The Regis School of the Sacred Heart, Houston, Texas – 2012 to 2015.
- Board Member, Annunciation Orthodox School, Houston, Texas – 2011 to 2015.
- Foundation Board Member, St. Agnes Academy, Houston, Texas – 2015 to Present.



**Jorge Ramirez**  
**Principal**  
**H.I.G. BioHealth Partners**

Jorge Ramirez is a Principal at H.I.G. BioHealth Partners and focuses on development stage and growth investments in the healthcare sector. Previously, Jorge was with ProQuest Investments, a healthcare focused private equity firm. During his eight years with ProQuest, the firm raised and fully invested two funds totaling \$625 million. Jorge represented ProQuest as an observer or board member in several successful companies including: Eagle Pharmaceuticals (NASDAQ: EGRX); Mevion Medical Systems; Revision Optics; and MethylGene (now, Mirati Pharmaceuticals: NASDAQ: MRTX). He currently serves on the advisory board of the Commercialization Center for Innovative Technologies, a life sciences incubator funded by the NJ Economic Development Authority.

Jorge has also held operating roles in healthcare companies. He was the General Manager of Neurology Products at Cyberkinetics Neurotechnology Systems. He led the regulatory and clinical development teams for an epilepsy monitoring device and had P&L responsibility for Cyberkinetics' research products. Previously, Jorge was a management consultant at Monitor Company.

Jorge earned degrees in Neuroscience and Spanish literature from Amherst College, where he graduated magna cum laude. He earned an M.B.A. from Harvard Business School, where he was a Pfizer Scholar and Social Enterprise Fellow.



**Mark Rosenblum**  
**Executive Vice President Finance & Interim CFO**  
**Salarius Pharmaceuticals**

Mr. Rosenblum is an accomplished financial executive with over 30 years senior management experience within the healthcare and chemical manufacturing industries. Prior to joining Salarius, Mr. Rosenblum served as Chairman, Chief Executive Officer and Director of ActiveCare as well as the Chief Financial Officer of Advaxis. Mr. Rosenblum was employed by Wellman for nearly 20 years, which was later acquired by DAK Americas, serving in various capacities including Chief Accounting Officer. Mr. Rosenblum began his career with Haskins & Sells, CPA (currently known as Deloitte), was a licensed Certified Public Accountant for over 30 years and is currently a member of the American Institute of Certified Public Accountants. Mr. Rosenblum holds both a Masters in Accountancy and a B.S. degree in Accounting from the University of South Carolina.



**Chad Rubin**  
**Managing Director**  
**Solebury Trout**

Chad has more than 18 years of experience in advising life science companies on topics including shareholder targeting, investor roadshows, capital markets transactions, messaging, and scenario analysis. His experience includes work in finance, consulting and market analysis, helping clients move from creation to follow-on and convertible offerings to M&A/IPO. Chad is involved in capital transactions with corporate clients and has counseled clients on domestic and cross-border transactions, and binary data events.

Recent engagement and representation highlights include:

- Advised a Phase 2 oncology company on release of clinical data, including KOL support/ events, positioning and roadshows with the Wall Street community highlighting the data
- Managed multiple private offerings for private life sciences and ag biotech companies from series A through series C
- Managed 50M euro private placement for Genfit, a Euronext listed company with a Phase 3 trial ongoing in NASH
- Assisted multiple companies through the pre-IPO process including strategy and support around messaging, materials, investor and analyst roadshows, syndicate selection and organizational support
- Prior to joining Solebury Trout in 2005, Chad was the head of the Biotechnology Capital Markets Intelligence Group at Thomson Financial, assisting life sciences companies in their understanding of Wall Street as it pertains to financing transactions, sales and trading dynamics, and perception around clinical and regulatory events.



**Henry Skinner**  
**Senior Vice President, Venture**  
**Tekla Capital Management**

Henry Skinner joined TCM in October of 2017. Previously, Dr. Skinner spent 7 years at Novartis Services where he was Vice President and Deputy Head and Managing Director of the Novartis Venture Fund, leading the diligence and investments in innovative life-science companies. Prior to his roles at the Novartis Venture Fund, he was the Executive Director, Head Strategic Alliances at Novartis Institutes for Biomedical Research. Prior to working at Novartis, Dr. Skinner was the Chief Executive Officer at SelectX Pharmaceuticals, President and Chief Executive Officer at NeoGenesis

## SPEAKERS | 2019 TEXAS LIFE SCIENCE FORUM

Pharmaceuticals and also spent four years at Pfizer in the Technology Acquisitions and Operations group. Dr. Skinner holds a B.S. and M.S. in Biology/Biotechnology from Worcester Polytechnic Institute, an M.S. and Ph.D. in Microbiology from the University of Illinois and a Postdoctoral in Molecular and Human Genetics from Baylor College of Medicine.

Dr. Skinner is responsible for investment research and due diligence in the biotechnology, medical device and diagnostic areas and serves as a member of the team responsible for making and executing on venture investments on behalf of the Funds.



**Michael Spector**  
**Managing Director**  
**Nasdaq**

Michael is a Managing Director with Nasdaq's Corporate Services team, responsible for managing relationships with Nasdaq listed companies in the South Central and Southwestern U.S. Additionally, Michael partners with private companies to help them access and navigate the public markets, supporting them from Initial Public Offering and beyond. Prior to taking on his role, Michael was the lead analyst on Nasdaq's Corporate Advisory Real Estate Team working with Real Estate companies of all capitalization sizes in a consultative capacity. He has been interviewed as a subject matter expert for publications such as Investor's Business Daily, Barrons, IR Magazine, and REIT Magazine. He frequently presents and moderates panels at industry conferences. Michael graduated Summa Cum Laude from Arizona State University with a B.S. in Behavioral Sciences and is a member of the Wildlife Conservation Society.



**Ann Tanabe**  
**Chief Executive Officer**  
**BioHouston**

Ann Tanabe was appointed CEO of BioHouston in October 2015 after serving four years as the company's COO. Prior to joining BioHouston in 2011, Ann served as vice president of investor relations at Synthesis Energy Systems, a publicly traded alternative energy company from May 2008 to December 2010.

Prior to this position, Ann served as vice president of corporate communications and investor relations and investor relations director at Encysive Pharmaceuticals, a publicly traded biotechnology company from July 2003 to May 2008.

From October 2000 to July 2003, Ann served as investor relations manager and corporate communications coordinator to Texas Biotechnology, the predecessor company to Encysive Pharmaceuticals. Prior to 2000, Ann held a variety of positions at Rochem Separation Systems. Ann earned a BA degree from Loyola Marymount University.



**Jaye Thompson, Ph.D.**  
**Co-Founder & COO**  
**Proxima Clinical Research**

Dr. Jaye Thompson is a Co-Founder and the Chief Operating Officer at Proxima. She has 25+ years of experience in the healthcare industry.

She is an entrepreneur and has been an executive at several biotech companies: Synergos Inc (Founder, acquired by inVentiv Health), Opexa Therapeutics, and Repros Therapeutics. Jaye is a biostatistician with clinical trial and regulatory expertise and has a history of assisting emerging companies meet their milestones.



**Clay Thorp**  
**General Partner**  
**Hatteras Ventures**

Clay is an entrepreneur turned venture capitalist. Since 1995, he has co-founded eight companies in the life science arena and co-founded Hatteras in 2000. Since co-founding Hatteras, Clay has been instrumental in building the firm from its origins with a \$3 million seed fund to a venture capital partnership that manages over \$550 million across six venture funds. Clay has led investments in a range of life science companies, including biopharmaceuticals, medical devices, diagnostics, and research informatics.

Clay began his career in 1995 when he co-founded Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for direct analysis of DNA, RNA and proteins. Shortly thereafter, he co-founded Novalon Pharmaceutical Corporation, where he led financing efforts and was head of business development from inception until Novalon's sale to Karo Bio for \$106.7 million in May of 2000. Subsequently, Clay applied his entrepreneurial passions to co-founding Hatteras Venture Partners (formerly Catalista Ventures). Since that time, Hatteras has invested in over 60 companies in the life science industry, serving as the founding or first institutional investor in over half of these. Clay has led investments and numerous strategic transaction processes in a variety of portfolio companies, including G1 Therapeutics, Clearside Biomedical, Lysosomal Therapeutics, Inc., Asthmatx, Inc., PhaseBio Pharmaceuticals, ArtusLabs, Embrella, and Synthematix, Inc. In the latter case, Clay served as CEO and Chairman from inception in 2000 until the company was acquired in April 2005 by Symyx Technologies (SMMX).

Clay currently serves as Chairman of PhaseBio Pharmaceuticals (PHAS). He is also on the boards of Clearside Biomedical (Nasdaq: CLSD), GeneCentric Therapeutics, Rodin Therapeutics, Lysosomal Therapeutics, and Orig3n. He is also on the Strategic and Scientific Advisory Board of Bria Biosciences. Clay serves on the Chancellor's Philanthropic Committee at UNC-Chapel Hill, the Board of Visitors of the Lineberger Comprehensive Cancer Center at UNC-Chapel Hill, and on the board of the NC School of Science and Mathematics Foundation. He holds a Masters of Public Policy from Harvard University and a B.A. in mathematics and art history from the University of North Carolina at Chapel Hill.



**Brian Togli**  
**President & CEO**  
**Galiot Insurance**

Brian Togli advises clients on their various exposures to loss during each phase of business development and leverages his relationship in the marketplace to deliver comprehensive insurance solutions. He has close to 15 years of risk management experience and has been specifically focusing on the life science industry since 2013. Beyond his role at Galiot, Togli is actively involved in the life science ecosystem in Houston through attending events, supporting BIO Houston and lending his expertise on topics such as Insurance 101 for Biotech Startups, 21 CFR Part 11/Cyber Security and International Clinical Trials. Togli holds 2 degrees from Pepperdine University in Business (BS) and Political Science (BA).



**Atul Varadhachary, M.D., Ph.D.**  
**Managing Partner**  
**Fannin Innovation Studio**

Atul Varadhachary M.D., PH.D. has served as Managing Partner at Fannin Innovation Studio since 2013 and leads Fannin's business innovation and technology commercialization efforts. Before Fannin, Atul was President of U.S. Operations at Reliance Life Sciences, part of the Reliance Group, India's largest corporation. Atul served for nine years as President & COO of Agennix, Inc., a late-stage biotechnology company. As product development and regulatory lead, he helped advance Agennix's lead molecule from preclinical studies into pivotal Phase 3 human studies and lead a successful sale of the company.

Before Agennix, Atul was Senior Engagement Manager at McKinsey & Co. where he co-led initiatives to support life science commercialization at Houston's Texas Medical Center. He co-founded and ran Pratham Health (now the Niramaya Health Foundation), a preventive health program reaching 65,000 under-served pre-school children in India, while on leave of absence from McKinsey. Atul was a Pratham USA founding director and past President.

q

Atul is active in Houston's biotech and commercialization ecosystem. He has served as an Adjunct Professor at Rice University, Baylor College of Medicine and the UT School of Public Health, and on several company and community Boards including BioHouston, the Harris Health System, TIE Houston, and the Indo-American Chamber of Commerce of Greater Houston (IACCGH) where he also served as President. He serves on the Greater Houston Partnership's Healthcare Advisory Committee and on the Jones Health Care Advisory Board.

Atul received his medical training at the University of Bombay. He earned a Ph.D. in Physiology followed by a postdoctoral fellowship in Biological Chemistry, both at Johns Hopkins School of Medicine, where he was founding President of the Johns Hopkins Postdoctoral Association, the first such organization in the country.



**Francesca Vitelli, Ph.D.**  
**Head, Viral Vector Process Development**  
**Lonza**



**Jeffrey Wade**  
**Vice President, Corporate & Administrative Affairs & CFO**  
**Lexicon Pharmaceuticals**

Jeffrey L. Wade has been Lexicon Pharmaceuticals' executive vice president, corporate and administrative affairs and chief financial officer since February 2015 and previously served in a series of finance and legal leadership positions since joining our company in 1999. Mr. Wade was previously a corporate securities and finance attorney for ten years with the law firm of Andrews & Kurth L.L.P., where he represented companies in the biotechnology, information technology and energy industries. Mr. Wade is a member of the board of directors of the Texas Healthcare and Bioscience Institute. He received his B.A. and J.D. from the University of Texas.



**Sandy Wallis**  
**Managing Director**  
**HX Venture Fund**

Sandy Wallis is a Managing Director at HX Venture Fund in Houston, Texas. Sandy is also a co-founder and Managing Director at Weathergage Capital, a venture capital fund of funds managing approximately \$1 billion in venture partnership commitments. Prior to Weathergage, she was a Principal of venture fund of funds Knightsbridge Advisers. Prior to Sandy's venture fund of funds experience, she was a consultant with Andersen Consulting and BSG Consulting. Sandy was also responsible for developing the first web-based IT architecture and strategy, and for developing the first global diversity strategy at Phillips Petroleum (now ConocoPhillips).

Sandy has an M.B.A from the Kellogg Graduate School of Management and a B.A., cum laude, from the University of the South, Sewanee. Following her undergraduate degree, Sandy was awarded a one-year research Fellowship with the Thomas J. Watson Foundation. As a Watson Fellow, she studied business management in Japan, India, and Australia. She is also a graduate of the Venture Capital Institute.

Sandy currently serves as a Steering Committee Member of Ignite Healthcare Network, as a Trustee for The University of the South, and as Board Member of Lawndale Arts Center.



**Bob Whitehead**  
**Co-Founder & Director**  
**Sprout Pharmaceuticals**

Robert Whitehead is a co-founder of Sprout Pharmaceuticals and currently serves as its Chief Operating Officer and as a member of its board of directors. He co-founded and served as Chief Operating Officer, Vice Chairman and member of the board of directors of Sprout until Sprout's acquisition in August 2015. He co-founded and served as Chief Executive Officer and director of Slate until Slate's acquisition in December 2011. From June 2004 to March 2005, he served as President and Chief Operating Officer of Auxilium Pharmaceuticals, Inc., a publicly traded specialty pharmaceutical company in the fields of urology and men's health. From June 2003 to March 2004, Mr. Whitehead served in executive capacities at Prestwick Pharmaceuticals, Inc., a specialty pharmaceutical company, ZymoGenetics, Inc., a biopharmaceutical company, Dura Pharmaceuticals and Élan Pharmaceuticals, Inc., which acquired Dura Pharmaceuticals in 2000. Mr. Whitehead received his B.S. from Temple University.



**Angela Wilkins, Ph.D.**  
**Co-CEO, CTO, & Founder**  
**Mercury Data Science**

Angela Wilkins is the founder and Chief Scientist at Mercury Data Science (MDS) where she works with Mercury's portfolio companies to identify solutions for complex data problems. Prior to MDS, Angela was a member of faculty research at Baylor College of Medicine and led projects at the policy think tank, Center of Science and Law. She developed her machine learning knowledge in the biomedical field as part of IBM's Watson AI and DARPA Simplex Project. Angela received her M.S and Ph.D. from Lehigh University, all in Theoretical Physics.



**Christie Williams, M.S.**  
**VP Program Operations**  
**FUJIFILM Diosynth Biotechnologies**

Christie Williams is the Vice President of Program Operations at Fujifilm Diosynth Biotechnologies Texas (FDBT). She is the leader of the Advanced Therapies Manufacturing and Program Delivery teams at FDBT, a leading Biologics Contract, Development, and Manufacturing Organization (CDMO), with sites in Texas, North Carolina, England, and Denmark. Christie is an honors graduate from the Missouri University of Science and Technology with a Master's degree in Chemical Engineering.

About: 2 parts VP (vigorously patient, vitally persistent), 2 parts problem solver, 3 parts team builder, 5 parts joy, 1 part private pilot, and 2.5 parts construction artist.

Motto: The whole is greater than the sum of the parts.

Christie has worked in the Bio CDMO industry for +20 years, with experience ranging from Process Development to Corporate Compliance and from Commercial Sales to Lean Six Sigma. She thrives in pulling from the strengths of people and processes to achieve goals. A strong believer in the power of choice, Christie is a champion for getting teams to do more of what matters and less of what does not.



**Jarrod Wrampe**  
**Process Utility Engineer**  
**CRB**

Jarrod is a project manager and process utility engineer at CRB, a global design, construction and consulting firm that relentlessly pursues and delivers success for clients in advanced technology industries. CRB was founded in 1984 as a single three-person office and has grown to a team of more than 1,100 passionate professionals in 17 offices throughout the world.

With nearly 19 years of experience, Jarrod is a subject matter expert for critical utilities including high purity water systems, process steam systems, liquefied and compressed gas systems, waste kill/neutralization systems, and process heat transfer systems. In his current role, he frequently functions as the client's primary interface for both design and project management. He also is responsible for the development of process and instrumentation diagrams (P&IDs), equipment specifications, equipment plans, piping plans and architectural drawings. Jarrod's experience as a design lead and project manager allow him to understand the entire project from inception to completion across multiple disciplines, making him an integral part of every phase of the design team.

Jarrod obtained Master of Science and Bachelor of Science degrees in Architectural Engineering from Kansas State University.